73 related articles for article (PubMed ID: 19155380)
1. Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions.
Smith EA; Carlos RC; Junck LR; Tsien CI; Elias A; Sundgren PC
AJR Am J Roentgenol; 2009 Feb; 192(2):W45-52. PubMed ID: 19155380
[TBL] [Abstract][Full Text] [Related]
2. Revisiting the use of proton magnetic resonance spectroscopy in distinguishing between primary and secondary malignant tumors of the central nervous system.
Farche MK; Fachinetti NO; da Silva LR; Matos LA; Appenzeller S; Cendes F; Reis F
Neuroradiol J; 2022 Oct; 35(5):619-626. PubMed ID: 35446177
[TBL] [Abstract][Full Text] [Related]
3. Development and aging of the cerebrum: assessment with proton MR spectroscopy.
Kadota T; Horinouchi T; Kuroda C
AJNR Am J Neuroradiol; 2001 Jan; 22(1):128-35. PubMed ID: 11158898
[TBL] [Abstract][Full Text] [Related]
4. Peak Resembling N-acetylaspartate (NAA) on Magnetic Resonance Spectroscopy of Brain Metastases.
Ostojic J; Kozic D; Panjkovic M; Georgievski-Brkic B; Dragicevic D; Lovrenski A; Boban J
Medicina (Kaunas); 2024 Apr; 60(4):. PubMed ID: 38674308
[No Abstract] [Full Text] [Related]
5. The choline/creatine ratio in five benign neoplasms: comparison with squamous cell carcinoma by use of in vitro MR spectroscopy.
Maheshwari SR; Mukherji SK; Neelon B; Schiro S; Fatterpekar GM; Stone JA; Castillo M
AJNR Am J Neuroradiol; 2000; 21(10):1930-5. PubMed ID: 11110549
[TBL] [Abstract][Full Text] [Related]
6. Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy.
Cianfoni A; Niku S; Imbesi SG
AJNR Am J Neuroradiol; 2007 Feb; 28(2):272-7. PubMed ID: 17296993
[TBL] [Abstract][Full Text] [Related]
7. Detection of choline signal in human breast lesions with chemical-shift imaging.
Baek HM; Chen JH; Yu HJ; Mehta R; Nalcioglu O; Su MY
J Magn Reson Imaging; 2008 May; 27(5):1114-21. PubMed ID: 18425841
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance spectroscopy of the frontal region in patients with metabolic syndrome: correlation with anthropometric measurement.
El-Mewafy ZMH; Razek AAKA; El-Eshmawy MM; El-Eneen NRA; El-Biaomy AAB
Pol J Radiol; 2018; 83():e215-e219. PubMed ID: 30627238
[TBL] [Abstract][Full Text] [Related]
9. MR spectroscopy in radiation injury.
Sundgren PC
AJNR Am J Neuroradiol; 2009 Sep; 30(8):1469-76. PubMed ID: 19369613
[TBL] [Abstract][Full Text] [Related]
10. Machine learning decision tree models for multiclass classification of common malignant brain tumors using perfusion and spectroscopy MRI data.
Vallée R; Vallée JN; Guillevin C; Lallouette A; Thomas C; Rittano G; Wager M; Guillevin R; Vallée A
Front Oncol; 2023; 13():1089998. PubMed ID: 37614505
[TBL] [Abstract][Full Text] [Related]
11. MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury.
Elias AE; Carlos RC; Smith EA; Frechtling D; George B; Maly P; Sundgren PC
Acad Radiol; 2011 Sep; 18(9):1101-8. PubMed ID: 21820634
[TBL] [Abstract][Full Text] [Related]
12. Multiparametric Characterization of Intracranial Gliomas Using Dynamic [18F]FET-PET and Magnetic Resonance Spectroscopy.
Pyka T; Krzyzanowska I; Rominger A; Delbridge C; Meyer B; Boeckh-Behrens T; Zimmer C; Gempt J
Diagnostics (Basel); 2022 Sep; 12(10):. PubMed ID: 36292019
[TBL] [Abstract][Full Text] [Related]
13. Magnetic Resonance Spectroscopy in Diagnosis and Follow-Up of Gliomas: State-of-the-Art.
Galijasevic M; Steiger R; Mangesius S; Mangesius J; Kerschbaumer J; Freyschlag CF; Gruber N; Janjic T; Gizewski ER; Grams AE
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804969
[TBL] [Abstract][Full Text] [Related]
14. Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma.
Chawla S; Bukhari S; Afridi OM; Wang S; Yadav SK; Akbari H; Verma G; Nath K; Haris M; Bagley S; Davatzikos C; Loevner LA; Mohan S
NMR Biomed; 2022 Jul; 35(7):e4719. PubMed ID: 35233862
[TBL] [Abstract][Full Text] [Related]
15. Pseudoprogression in Glioblastoma: Role of Metabolic and Functional MRI-Systematic Review.
Sidibe I; Tensaouti F; Roques M; Cohen-Jonathan-Moyal E; Laprie A
Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203493
[TBL] [Abstract][Full Text] [Related]
16. Early Detection of Radiation-Induced Injury and Prediction of Cognitive Deficit by MRS Metabolites in Radiotherapy of Low-Grade Glioma.
Alirezaei Z; Amouheidari A; Hassanpour M; Davanian F; Iraji S; Shokrani P; Nazem-Zadeh MR
Biomed Res Int; 2021; 2021():6616992. PubMed ID: 34258272
[TBL] [Abstract][Full Text] [Related]
17. Nomograms for predicting progression-free survival and overall survival after surgery and concurrent chemoradiotherapy for glioblastoma: a retrospective cohort study.
Zheng L; Zhou ZR; Shi M; Chen H; Yu QQ; Yang Y; Liu L; Zhang L; Guo Y; Zhou X; Li C; Wei Q
Ann Transl Med; 2021 Apr; 9(7):571. PubMed ID: 33987269
[TBL] [Abstract][Full Text] [Related]
18. Late effects of cancer treatment: consequences for long-term brain cancer survivors.
Alemany M; Velasco R; Simó M; Bruna J
Neurooncol Pract; 2021 Feb; 8(1):18-30. PubMed ID: 33664966
[TBL] [Abstract][Full Text] [Related]
19. Evaluating Magnetic Resonance Spectroscopy as a Tool for Monitoring Therapeutic Response of Whole Brain Radiotherapy in a Mouse Model for Breast-to-Brain Metastasis.
Chae WH; Niesel K; Schulz M; Klemm F; Joyce JA; Prümmer M; Brill B; Bergs J; Rödel F; Pilatus U; Sevenich L
Front Oncol; 2019; 9():1324. PubMed ID: 31828043
[TBL] [Abstract][Full Text] [Related]
20. Standardized MRI assessment of high-grade glioma response: a review of the essential elements and pitfalls of the RANO criteria.
Yang D
Neurooncol Pract; 2016 Mar; 3(1):59-67. PubMed ID: 31579522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
